EU Policies & Directives
-
Social Health Protection
Despite considerable attention over many decades, striking inequalities among and within countries still exist. Several social factors that can influence health can be found in the image below. The Social…
Read More » -
Orphan Drugs
The Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) is responsible for receiving, approving, and/or rejecting orphan drugs’ designation applications. Markets’ access to Orphan Drugs varies between…
Read More » -
Rare Diseases
In EU countries, any disease affecting fewer than 5 people in 10 000 is considered rare. This number may seem small but it translates into approximately 246.000 people throughout the…
Read More » -
Cross-Border Healthcare
The Directive 2011/24/EU, clarifies that EU patients seeking healthcare outside their country may do so as long as the type of treatment would have been normally provided at home. Payment…
Read More » -
Clinical Trials
Best Practices Guidance for Clinical Trials In September 2024, the World Health Organization (WHO) released groundbreaking guidelines to strengthen the design, conduct, and oversight of Clinical Trials globally. This…
Read More » -
Pharmacovigilance
Phamacovigilance is defined as the activities that deal with the detection, assessment, understanding and prevention of adverse effects of medicinal products in consumers, simultaneously undertaking the monitoring of counterfeit products…
Read More » -
Patient Safety
Every year, millions of patients suffer injuries or die because of unsafe and poor-quality health care. Many medical practices and risks associated with health care are emerging as major challenges…
Read More » -
Blood Safety & Availability
Blood Availability Great variability exists regarding availability of blood and blood donation practices among countries, influenced by socioeconomical factors. In high-income countries, blood collection tends to be a well-established practice…
Read More »